Business Description
![Genmab A/S Genmab A/S logo](https://static.gurufocus.com/logos/0C00000X4R.png?14)
Genmab A/S
ISIN : DK0010272202
Share Class Description:
OCSE:GMAB: Ordinary SharesCompare
Compare
Traded in other countries / regions
GMAB.USAGMAB.Denmark0MGB.UKGE91.GermanyGMAB.AustriaGMAB.Mexico IPO Date
2000-10-01Description
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 29.29 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.14 | |||||
Interest Coverage | 203.04 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 18.8 | |||||
Beneish M-Score | -2.5 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 17.7 | |||||
3-Year EBITDA Growth Rate | -1.2 | |||||
3-Year EPS without NRI Growth Rate | -2.7 | |||||
3-Year FCF Growth Rate | 4.6 | |||||
3-Year Book Growth Rate | 18.3 | |||||
Future 3-5Y EPS without NRI Growth Rate | 23.17 | |||||
Future 3-5Y Total Revenue Growth Rate | 24.17 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 18.29 | |||||
9-Day RSI | 24.97 | |||||
14-Day RSI | 29.77 | |||||
6-1 Month Momentum % | -10.27 | |||||
12-1 Month Momentum % | -23.57 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 12.46 | |||||
Quick Ratio | 12.42 | |||||
Cash Ratio | 10.72 | |||||
Days Inventory | 63.05 | |||||
Days Sales Outstanding | 94.3 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | 0.35 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 97.69 | |||||
Operating Margin % | 32.01 | |||||
Net Margin % | 30.69 | |||||
FCF Margin % | 30.16 | |||||
ROE % | 18.03 | |||||
ROA % | 16.07 | |||||
ROIC % | 93.64 | |||||
ROC (Joel Greenblatt) % | 177.77 | |||||
ROCE % | 22.53 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 21.08 | |||||
Forward PE Ratio | 22.94 | |||||
PE Ratio without NRI | 22.67 | |||||
Shiller PE Ratio | 40.19 | |||||
Price-to-Owner-Earnings | 27.51 | |||||
PEG Ratio | 0.87 | |||||
PS Ratio | 6.47 | |||||
PB Ratio | 3.5 | |||||
Price-to-Tangible-Book | 3.5 | |||||
Price-to-Free-Cash-Flow | 21.45 | |||||
Price-to-Operating-Cash-Flow | 20.31 | |||||
EV-to-EBIT | 11.58 | |||||
EV-to-Forward-EBIT | 13.51 | |||||
EV-to-EBITDA | 11.58 | |||||
EV-to-Forward-EBITDA | 12.07 | |||||
EV-to-Revenue | 4.63 | |||||
EV-to-Forward-Revenue | 4.18 | |||||
EV-to-FCF | 15.34 | |||||
Price-to-Projected-FCF | 1.47 | |||||
Price-to-DCF (Earnings Based) | 0.6 | |||||
Price-to-DCF (FCF Based) | 0.56 | |||||
Price-to-Median-PS-Value | 0.27 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.91 | |||||
Price-to-Graham-Number | 1.88 | |||||
Price-to-Net-Current-Asset-Value | 3.77 | |||||
Price-to-Net-Cash | 4.48 | |||||
Earnings Yield (Greenblatt) % | 8.64 | |||||
FCF Yield % | 4.84 | |||||
Forward Rate of Return (Yacktman) % | 23.56 |